Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Opthea Ltd Major Shareholding Notification 2012

Jul 16, 2012

32698_rns_2012-07-16_5d774f66-e276-48f2-b7f8-096836e3ebc1.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

==> picture [211 x 55] intentionally omitted <==

17 JULY 2012

The Companies Section The Australian Stock Exchange Limited 525 Collins Street MELBOURNE VIC 3000

Update to Substantial Holding Notice for Antisense Therapeutics Limited

We enclose Form 604 “Notice of Change of Interests of Substantial Holder” with respect to holdings in Antisense Therapeutics Limited by Polychip Pharmaceuticals Pty Ltd (Polychip) (a wholly owned subsidiary of Circadian Technologies Limited) and Syngene Limited (a subsidiary - 51.67% owned by Polychip).

Yours faithfully

Susan Madden

Company Secretary

Circadian Technologies Limited

Level 1 10 Wallace Avenue Toorak Victoria 3142 Australia T +61 (3) 9826 0399 F +61 (3) 9824 0083 www.circadian.com.au

ABN 32 006 340 567

FORM 604

Corporations Act 2001 Section 671B

NOTICE OF CHANGE OF INTERESTS OF SUBSTANTIAL HOLDER


To: ANTISENSE THERAPEUTICS LIMITED (ANP)

ACN: 095 060 745

1. Details of substantial holder (1)

Name: POLYCHIP PHARMACEUTICALS PTY LTD (POLYCHIP) (A WHOLLY OWNED SUBSIDIARY OF CIRCADIAN TECHNOLOGIES LIMITED): AND SYNGENE LIMITED (SYNGENE) (51.67% OWNED BY POLYCHIP)

ACN: 006 455 456 (POLYCHIP) 006 161 753 (SYNGENE)

There was a change in the interests of the substantial holder : Due to dilution on: 13/07/2012 The previous notice was given to the company on: 29/03/2012 The previous notice was dated: 29/03/2012

2. Previous and present voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities
(4)
Previous notice Previous notice Previous notice Present notice Present notice
Person’s votes Voting power (5) Person’s votes Voting power (5)
Ordinary:
Polychip
Syngene LimitedA
Total
101,906,497
34,009,412
135,915,909
8.98%
3.00%
11.98%
101,906,497
41,242,690
143,149,187
7.85%
3.18%
11.03%

A Polychip Pharmaceuticals Pty Ltd has a 51.67% interest in Syngene Limited (previously 52.52%). Syngene Limited owns 41,242,690 ordinary shares in Antisense Therapeutics Limited. The net movement in substantial holding was 1.06%.

3. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of
change
Person whose
relevant interest
changed
Nature of change (6) Consideration
given in
relation to
change (7)
Class and
number of
securities
affected
Person’s
votes
affected
(no. of
shares)
02/04/12 Polychip &Syngene New share issue of 107,000
ordinary shares by ANP
which diluted each of
Polychip’s and Syngene’s
respective interests in ANP.
N/A Number of
ordinary
shares not
affected.
Number of
votes/
shares not
affected.
27/04/12 Polychip &Syngene New share issue of 19,400
ordinary shares by ANP
which diluted each of
Polychip’s and Syngene’s
respective interests in ANP.
N/A Number of
ordinary
shares not
affected.
Number of
votes/
shares not
affected.
07/05/12 Polychip &Syngene New share issue of
130,685,221 ordinary
shares by ANP which
diluted each of Polychip’s
and Syngene’s respective
interests in ANP.
N/A Number of
ordinary
shares not
affected.
Number of
votes/
shares not
affected.
07/05/12 Syngene Allotment of Tranche 2
8,333,278 ordinary ANP
shares to Syngene which
has increased Syngene’s
interests in ANP.
$149,999.99 8,333,278
ordinary
shares.
8,333,278
votes.
29/05/12 Polychip &Syngene New share issue of 42,622
ordinary shares by ANP
which diluted each of
Polychip’s and Syngene’s
respective interests in ANP.
N/A Number of
ordinary
shares not
affected.
Number of
votes/
shares not
affected.
22/06/12 Polychip &Syngene New share issue of 17,010
ordinary shares by ANP
which diluted each of
Polychip’s and Syngene’s
respective interests in ANP.
N/A Number of
ordinary
shares not
affected.
Number of
votes/
shares not
affected.
03/07/12 Polychip &Syngene New share issue of
1,984,370 ordinary shares
by ANP which diluted each
of Polychip’s and
Syngene’s respective
interests in ANP.
N/A Number of
ordinary
shares not
affected.
Number of
votes/
shares not
affected.
09/07/12 Syngene Sale of 1,100,000 ordinary
ANP shares by Syngene
which has decreased
Syngene’s interests in ANP.
$27,500.00 1,100,000
ordinary
shares.
1,100,000
votes.
13/07/12 Polychip & Syngene New share issue of
30,647,565 ordinary shares
by ANP which diluted each
of Polychip’s and
Syngene’s respective
interests in ANP.
N/A Number of
ordinary
shares not
affected.
Number of
votes/
shares not
affected.

4. Present relevant interests

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant
interest
Registered holder
of securities
Person entitled to
be registered as
holder (8)
Nature of
relevant
interest (6)
Class and
number of
securities
Person’s
votes
Polychip
Pharmaceuticals
PtyLtd
Polychip
Pharmaceuticals Pty
Ltd
Polychip
Pharmaceuticals
PtyLtd
Beneficial
Owner
Ordinary
shares
101,906,497
101,906,497
Syngene Limited
(Polychip has a
51.67% interest in
Syngene)
Syngene Limited Syngene Limited Beneficial
Owner
Ordinary
shares
41,242,690
41,242,690

5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN (ifapplicable) **Nature of association **
Not applicable

6. Addresses

The addresses of persons named in this form are as follows:

Name Address (Registered Office)
PolychipPharmaceuticals PtyLtd Level 1,10 Wallace Avenue,Toorak,Victoria
Circadian Technologies Limited Level 1,10 Wallace Avenue,Toorak,Victoria
Syngene Limited Level 1,10 Wallace Avenue,Toorak,Victoria

Signed by:

Susan Madden Company Secretary 17 July 2012